New data from Moderna Inc's large Covid-19 vaccine trial shows that the protection it offers wanes over time, supporting the case for booster doses, the company said in a news release.
"This is only one estimate, but we do believe this means as you look toward the fall and winter, at minimum we expect the estimated impact of waning immunity would be 600,000 additional cases of Covid-19," Moderna President Stephen Hoge said in a conference call with investors.
Hoge said data from its booster studies shows the vaccine could increase neutralising antibodies to levels even higher than were seen after the second dose.
Read the full Reuters story here.
